Andexxa (Ondexxya) Market Trends Are Creating New Opportunities For Industry Leaders
Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Andexxa (Ondexxya) Market Size Forecast: How Large Could The Market Become By 2030?
The historic expansion was driven by the widespread adoption of Factor Xa inhibitors, incidents requiring emergency bleeding management, the regulatory authorization of reversal agents, growing demand for critical care in hospitals, and an aging demographic.
Several factors are expected to drive growth during the forecast period, including the rising prevalence of cardiovascular diseases, a greater number of anticoagulant prescriptions, the expansion of trauma care, enhancements in emergency response protocols, and an increase in surgical procedures. Key trends shaping this period involve a growing demand for anticoagulant reversal agents, developments in emergency bleeding management, the adoption of hospital-focused critical care treatments, more widespread utilization of factor Xa inhibitors, and a heightened emphasis on rapid hemostasis solutions.
Download A Free Sample Report For Comprehensive Market Insights:
Andexxa (Ondexxya) Market Growth Drivers: What Factors Are Accelerating Expansion?
The growth in bleeding disorders is anticipated to drive the expansion of the andexxa (ondexxya) market in the coming period. Bleeding disorders encompass a variety of medical conditions that hinder the blood’s ability to form clots effectively, causing either prolonged or excessive bleeding. This rise can be linked to factors like enhanced diagnostic methods, heightened awareness, genetic predispositions, and an aging demographic, all contributing to more frequent identification of these conditions. Andexxa (Ondexxya) is essential for managing bleeding disorders due to its ability to quickly counteract the anticoagulant effects of factor Xa inhibitors, thereby averting dangerous bleeding in urgent scenarios. For example, data from the National Blood Authority, an Australian blood management organization, showed that in July 2025, 2,797 patients were diagnosed with von Willebrand disease (VWD) in 2023–2024, compared to 2,669 in 2022–2023. Consequently, the rising prevalence of bleeding disorders is fueling the growth of the andexxa (ondexxya) market.
The expanding geriatric population is set to drive the growth of the andexxa (ondexxya) market moving ahead. The geriatric population consists of individuals aged 65 and over, who often encounter age-related health issues such as chronic illnesses, cognitive decline, and difficulties with mobility. This demographic is growing worldwide because of longer life expectancies and healthcare advancements. Andexxa (Ondexxya) proves beneficial for elderly individuals by reversing bleeding triggered by blood thinners, which are frequently prescribed to older adults for conditions like atrial fibrillation. As per a October 2022 report from the World Health Organization (WHO), a global public health authority based in Switzerland, one in six people globally will be aged 60 or older by 2030, and by 2050, the number of people aged 60 and over will reach 2.1 billion. Thus, the increasing geriatric population is propelling the expansion of the andexxa (ondexxya) market.
Andexxa (Ondexxya) Market Segment Landscape And Growth Potential
The andexxa (ondexxya) market covered in this report is segmented –
1) By Indication: Reversal Of Bleeding Caused By Factor Xa Inhibitors, Acute Major Bleeding Events, Emergency Surgery Or Procedures
2) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
3) By End User: Adult, Geriatric, Pediatric
Andexxa (Ondexxya) Market Trends: What Is Shaping Future Industry Growth?
Key players in the Andexxa market are prioritizing the development of advanced anticoagulant reversal therapies aimed at improving patient outcomes during severe bleeding episodes. Reversal therapy is a specialized approach that counteracts the effects of anticoagulant medications, swiftly restoring normal blood clotting and minimizing the likelihood of fatal hemorrhage. For example, in January 2024, AstraZeneca India secured approval from the CDSCO to import and market andexanet alfa for use in life-threatening or uncontrolled bleeding triggered by Factor Xa inhibitors like apixaban and rivaroxaban. This newly approved treatment involves an initial intravenous bolus administered over 15 to 30 minutes, followed by a two-hour infusion. Clinical studies on major bleeding have shown that andexanet alfa is both effective and safe, enabling the prompt resumption of anticoagulation therapy after an incident, exhibiting good tolerability, and fulfilling a significant unmet need among patients using novel oral anticoagulants.
Andexxa (Ondexxya) Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the andexxa (ondexxya) market are AstraZeneca Plc
Access The Complete Andexxa (Ondexxya) Market Report:
Andexxa (Ondexxya) Market Largest Region By Revenue And Market Share
North America was the largest region in the andexxa (ondexxya) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the andexxa (ondexxya) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
